Full Text Journal Articles by
Author Victoria Atkinson

Advertisement

Find full text journal articles






Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.

Georgina V Long, Caroline Robert, Marcus O Butler, Felix Couture, Matteo S Carlino, Steven O'Day, Victoria Atkinson, Jonathan S Cebon, Michael P Brown, Stephane Dalle, Andrew G Hill, Geoffrey T Gibney, Steven McCune, Alexander M Menzies, Cuizhen Niu, Nageatte Ibrahim, Blanca Homet Moreno, Adi Diab,

<h4>Purpose</h4>Standard-dose pembrolizumab plus alternative-dose ipilimumab (1 mg/kg Q3W for 4 doses) was tolerable and had robust antitumor activity in advanced melanoma in cohort B of the phase 1 KEYNOTE-029 study. Cohort C evaluated standard-dose pembrolizumab with two other alternative ipilimumab regimens.<h4>Experimental design</h4>Patients with treatment-naive unresectable stage III/IV melanoma were randomly ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy.

B Mark Smithers, Robyn P M Saw, David E Gyorki, Richard C W Martin, Victoria Atkinson, Andrew Haydon, Rachel Roberts-Thomson, John F Thompson,

Australia and New Zealand have the highest incidence and mortality rates for melanoma in the world. Local surgery is still the standard treatment of primary cutaneous melanoma, and it is therefore important that surgeons understand the optimal care pathways for patients with melanoma. Accurate staging is critical to ensure a ... Read more >>

ANZ J Surg (ANZ journal of surgery)
[2021, 91 Suppl 2:3-13]

Cited: 0 times

View full text PDF listing >>



Advertisement

Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.

Adriana Hepner, Victoria G Atkinson, James Larkin, Rebecca A Burrell, Matteo S Carlino, Douglas B Johnson, Lisa Zimmer, Katy K Tsai, Oliver Klein, Serigne N Lo, Andrew Haydon, Prachi Bhave, Megan Lyle, Lalit Pallan, Ines Pires da Silva, Camille Gerard, Olivier Michielin, Georgina V Long, Alexander M Menzies,

<h4>Purpose</h4>Combination immunotherapy with nivolumab and ipilimumab has a high initial response rate in advanced melanoma; however, up to 55% of patients later progress. The efficacy and safety of ipilimumab re-induction in the setting of acquired resistance (AR) to combination immunotherapy is unknown.<h4>Methods</h4>Patients with advanced melanoma who initially achieved a complete ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 153:213-222]

Cited: 0 times

View full text PDF listing >>



5-Year Outcomes with Cobimetinib Plus Vemurafenib in BRAF V600 Mutation-Positive Advanced Melanoma: Extended Follow-Up of the coBRIM Study.

Paolo A Ascierto, Brigitte Dreno, James Larkin, Antoni Ribas, Gabriella Liszkay, Michele Maio, Mario Mandal, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Jessie J Hsu, Surai Jones, Haocheng Li, Edward McKenna, Athina Voulgari, Grant A McArthur,

<h4>Purpose</h4>The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated <i>BRAF</i> <sup>V600</sup> mutation-positive advanced melanoma. We report long-term follow-up of coBRIM, with at least 5 years since the last patient ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2021, :]

Cited: 1 time

View full text PDF listing >>



Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy.

Helen Dearden, Lewis Au, Daniel Y Wang, Lisa Zimmer, Zeynep Eroglu, Jessica L Smith, Marcello Cuvietto, Chloe Khoo, Victoria Atkinson, Serigne Lo, Georgina V Long, Shahneen Sandhu, Paolo A Ascierto, Matteo S Carlino, Douglas B Johnson, James Larkin, Alexander M Menzies,

<h4>Background</h4>Combination ipilimumab and nivolumab is approved for several malignancies. Toxicity most often occurs 6-10 weeks into treatment. Whether very early toxicity is harder to manage or influences efficacy is unknown.<h4>Methods</h4>Consecutive metastatic melanoma patients who developed hyperacute toxicity, defined as Grade 2+ irAE within 21 days of receiving ipilimumab + anti-PD-1 were retrospectively ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 153:168-178]

Cited: 0 times

View full text PDF listing >>



A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III).

Victoria G Atkinson, Pietro Quaglino, Massimo Aglietta, Michele Del Vecchio, Roberta Depenni, Francesca Consoli, Dimitrios Bafaloukos, Pier Francesco Ferrucci, Skaiste Tulyte, Ivana Krajsová, Paolo A Ascierto, Rossana Gueli, Ana Arance, Helen Gogas, Hiya Banerjee, Teddy Saliba, Egbert de Jong, Bart Neyns,

The dabrafenib plus trametinib (dab + tram) combination has demonstrated durable long-term efficacy in patients with <i>BRAF</i> V600-mutant metastatic melanoma. However, real-world data characterizing patients with long-term benefit are limited. DESCRIBE III was a global, observational, retrospective, chart review study in patients with unresectable or metastatic melanoma treated with dab ... Read more >>

Cancers (Basel) (Cancers)
[2021, 13(10):]

Cited: 0 times

View full text PDF listing >>



Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.

Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U Blank, Mario Mandalà, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, Susana Puig, Paolo A Ascierto, James Larkin, Paul C Lorigan, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J M van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C J van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert, Alexander M M Eggermont, ,

<h4>Background</h4>The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43-0·74]; p<0·0001). This study reports the results from the health-related quality-of-life (HRQOL) exploratory endpoint.<h4>Methods</h4>This double-blind, ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2021, 22(5):655-664]

Cited: 0 times

View full text PDF listing >>



Survival of advanced melanoma patients treated with immunotherapy and targeted therapy: A real-world study.

Su-Yeon Yu, Dan Mckavanagh, Ian McPherson, Euan Walpole, Victoria Atkinson, Samantha Hollingworth,

<h4>Introduction</h4>We aimed to examine the survival outcomes plus patient and treatment characteristics of advanced melanoma patients treated with first-line immunotherapy (IT), targeted therapy (TT), and chemotherapy (CTH) and compare findings with information from pivotal trials for each therapy.<h4>Materials and methods</h4>We retrospectively reviewed the use of systematic IT, TT and CTH ... Read more >>

Pharmacoepidemiol Drug Saf (Pharmacoepidemiology and drug safety)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.

Judith M Versluis, Anne M Hendriks, Alison M Weppler, Lauren J Brown, Karlijn de Joode, Karijn P M Suijkerbuijk, Lisa Zimmer, Ellen W Kapiteijn, Clara Allayous, Douglas B Johnson, Adriana Hepner, Joanna Mangana, Prachi Bhave, Yanina J L Jansen, Claudia Trojaniello, Victoria Atkinson, Lucy Storey, Paul Lorigan, Paolo A Ascierto, Bart Neyns, Andrew Haydon, Alexander M Menzies, Georgina V Long, Celeste Lebbe, Astrid A M van der Veldt, Matteo S Carlino, Shahneen Sandhu, Harm van Tinteren, Elisabeth G E de Vries, Christian U Blank, Mathilde Jalving,

<h4>Introduction</h4>In patients with metastatic melanoma, progression of a single tumour lesion (solitary progression) after response to immune checkpoint inhibition (ICI) is increasingly treated with local therapy. We evaluated the role of local therapy for solitary progression in melanoma.<h4>Patients and methods</h4>Patients with metastatic melanoma treated with ICI between 2010 and 2019 ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 151:72-83]

Cited: 0 times

View full text PDF listing >>



Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients.

Lauren G Aoude, Bernadette Z Y Wong, Vanessa F Bonazzi, Sandra Brosda, Shaun B Walters, Lambros T Koufariotis, Marjan M Naeini, John V Pearson, Harald Oey, Kalpana Patel, Julia J Bradford, Conor J Bloxham, Victoria Atkinson, Phillip Law, Geoffrey Strutton, Gerard Bayley, Samuel Yang, B Mark Smithers, Nicola Waddell, Kenneth Miles, Andrew P Barbour,

Treatment for metastatic melanoma includes targeted and/or immunotherapy. Although many patients respond, only a subset has complete response. As late-stage patients often have multiple tumors in difficult access sites, non-invasive techniques are necessary for the development of predictive/prognostic biomarkers. PET/CT scans from 52 patients with stage III/IV melanoma were assessed ... Read more >>

Mol Cancer Res (Molecular cancer research : MCR)
[2021, 19(6):950-956]

Cited: 0 times

View full text PDF listing >>



Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

Ronan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, Thomas Zander, Eric Van Cutsem, Guillaume Piessen, Guillermo Mendez, Josephine Feliciano, Satoru Motoyama, Astrid Lièvre, Hope Uronis, Elena Elimova, Cecile Grootscholten, Karen Geboes, Syed Zafar, Stephanie Snow, Andrew H Ko, Kynan Feeney, Michael Schenker, Piotr Kocon, Jenny Zhang, Lili Zhu, Ming Lei, Prianka Singh, Kaoru Kondo, James M Cleary, Markus Moehler, ,

<h4>Background</h4>No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer.<h4>Methods</h4>We conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy in patients with esophageal or ... Read more >>

N Engl J Med (The New England journal of medicine)
[2021, 384(13):1191-1203]

Cited: 3 times

View full text PDF listing >>



Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.

Alexander M M Eggermont, Christian U Blank, Mario Mandalà, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J M van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul C Lorigan, Alexander C J van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert, ,

<h4>Background</h4>The European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. At 15-month median follow-up, pembrolizumab improved recurrence-free survival (hazard ratio [HR] 0·57 [98·4% CI 0·43-0·74], p<0·0001) compared with placebo, leading to its approval in the USA ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2021, 22(5):643-654]

Cited: 0 times

View full text PDF listing >>



Human CD141+ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model.

Yoke Seng Lee, Liam J O'Brien, Carina M Walpole, Frances E Pearson, Ingrid M Leal-Rojas, Kelly-Anne Masterman, Victoria Atkinson, Andrew Barbour, Kristen J Radford,

<h4>Background</h4>The conventional type 1 dendritic cell subset (cDC1) is indispensable for tumor immune responses and the efficacy of immune checkpoint inhibitor (ICI) therapies in animal models but little is known about the role of the human CD141<sup>+</sup> DC cDC1 equivalent in patients with melanoma.<h4>Methods</h4>We developed a flow cytometry assay to ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2021, 9(3):]

Cited: 1 time

View full text PDF listing >>



Reply to E. Hindié.

Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson, Stéphane Dalle, Andrew M Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger Koornstra, Leonel Hernandez-Aya, Anna Maria Di Giacomo, Alfonsus J M van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul C Lorigan, Alexander C J van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert,

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2021, 39(8):944-946]

Cited: 0 times

View full text PDF listing >>



KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma.

Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V Long, Rosalie Stephens, Inge Marie Svane, Michal Lotem, Mahmoud Abu-Amna, Eduard Gasal, Razi Ghori, Scott J Diede, Elizabeth S Croydon, Antoni Ribas, Paolo Antonio Ascierto, ,

<h4>Background</h4>In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet) improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib (doublet) without reaching statistical significance. Mature results on PFS, duration of response (DOR), and overall survival (OS) are reported.<h4>Methods</h4>The double-blind, phase 2 part of KEYNOTE-022 enrolled patients with previously untreated ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2020, 8(2):]

Cited: 3 times

View full text PDF listing >>



Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

Thierry André, Kai-Keen Shiu, Tae Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis Punt, Denis Smith, Rocio Garcia-Carbonero, Manuel Benavides, Peter Gibbs, Christelle de la Fouchardiere, Fernando Rivera, Elena Elez, Johanna Bendell, Dung T Le, Takayuki Yoshino, Eric Van Cutsem, Ping Yang, Mohammed Z H Farooqui, Patricia Marinello, Luis A Diaz, ,

<h4>Background</h4>Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 blockade as compared with chemotherapy as first-line therapy for MSI-H-dMMR advanced or metastatic colorectal cancer is unknown.<h4>Methods</h4>In this phase 3, open-label trial, 307 patients with metastatic MSI-H-dMMR colorectal ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 383(23):2207-2218]

Cited: 69 times

View full text PDF listing >>



Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients.

Lauren G Aoude, Vanessa F Bonazzi, Sandra Brosda, Kalpana Patel, Lambros T Koufariotis, Harald Oey, Katia Nones, Scott Wood, John V Pearson, James M Lonie, Melissa Arneil, Victoria Atkinson, B Mark Smithers, Nicola Waddell, Andrew P Barbour,

Patients with late stage resected cutaneous melanoma have poor overall survival (OS) and experience irreversible adverse events from systemic therapy. There is a clinical need to identify biomarkers to predict outcome. Performing germline/tumour whole-exome sequencing of 44 stage III/IV melanoma patients we identified pathogenic germline mutations in CDKN2A, CDK4, ATM, ... Read more >>

Sci Rep (Scientific reports)
[2020, 10(1):17687]

Cited: 1 time

View full text PDF listing >>



Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.

Prachi Bhave, Lalit Pallan, Georgina V Long, Alexander M Menzies, Victoria Atkinson, Justine V Cohen, Ryan J Sullivan, Vanna Chiarion-Sileni, Marta Nyakas, Katharina Kahler, Axel Hauschild, Ruth Plummer, Claudia Trojaniello, Paolo A Ascierto, Lisa Zimmer, Dirk Schadendorf, Clara Allayous, Celeste Lebbe, Andrea Maurichi, Mario Santinami, Severine Roy, Caroline Robert, Thierry Lesimple, Sapna Patel, Judith M Versluis, Christian U Blank, Adnan Khattak, Andre Van der Westhuizen, Matteo S Carlino, Mark Shackleton, Andrew Haydon,

<h4>Background</h4>Adjuvant targeted therapy (TT) improves relapse free survival in patients with resected BRAF mutant stage III melanoma. The outcomes and optimal management of patients who relapse after adjuvant TT is unknown.<h4>Methods</h4>Patients from twenty-one centres with recurrent melanoma after adjuvant TT were included. Disease characteristics, adjuvant therapy, recurrence, treatment at relapse ... Read more >>

Br J Cancer (British journal of cancer)
[2021, 124(3):574-580]

Cited: 0 times

View full text PDF listing >>



Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma.

Victoria Atkinson, Adnan Khattak, Andrew Haydon, Melissa Eastgate, Amitesh Roy, Prashanth Prithviraj, Christian Mueller, Chrystelle Brignone, Frederic Triebel,

<h4>Background</h4>To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab.<h4>Methods</h4>The study was divided into two parts; parts A and B, where part A was the dose escalation part and part B was ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2020, 8(2):]

Cited: 6 times

View full text PDF listing >>



Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia.

Angela M Hong, Cora Waldstein, Brindha Shivalingam, Matteo S Carlino, Victoria Atkinson, Richard F Kefford, Grant A McArthur, Alexander M Menzies, John F Thompson, Georgina V Long,

<h4>Introduction</h4>The brain is a common site of metastatic disease for patients with advanced melanoma. Brain metastasis portends a poor prognosis, often causing deterioration in neurological function and quality of life, and leading to neurological death. Treatment approaches including surgery, radiotherapy and systemic therapy can lead to better control of this ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2021, 142:10-17]

Cited: 1 time

View full text PDF listing >>



Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.

Reinhard Dummer, Celeste Lebbé, Victoria Atkinson, Mario Mandalà, Paul D Nathan, Ana Arance, Erika Richtig, Naoya Yamazaki, Caroline Robert, Dirk Schadendorf, Hussein A Tawbi, Paolo A Ascierto, Antoni Ribas, Keith T Flaherty, Neha Pakhle, Catarina D Campbell, Daniel Gusenleitner, Aisha Masood, Jan C Brase, Eduard Gasal, Georgina V Long,

Immune and targeted therapies achieve long-term survival in metastatic melanoma; however, new treatment strategies are needed to improve patients' outcomes<sup>1,2</sup>. We report on the efficacy, safety and biomarker analysis from the single-arm safety run-in (part 1; n = 9) and biomarker (part 2; n = 27) cohorts of the randomized, placebo-controlled, phase 3 COMBI-i trial ... Read more >>

Nat Med (Nature medicine)
[2020, 26(10):1557-1563]

Cited: 12 times

View full text PDF listing >>



Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.

Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M Arance, Stephane Dalle, C Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Iván Márquez-Rodas, Marcus O Butler, Michele Maio, Mark R Middleton, Luis de la Cruz-Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A Fecher, Michael Millward, Nikhil I Khushalani, Paola Queirolo, Maurice Lobo, Veerle de Pril, John Loffredo, James Larkin, Jeffrey Weber,

<h4>Background</h4>Previously, findings from CheckMate 238, a double-blind, phase 3 adjuvant trial in patients with resected stage IIIB-C or stage IV melanoma, showed significant improvements in recurrence-free survival and distant metastasis-free survival with nivolumab versus ipilimumab. This report provides updated 4-year efficacy, initial overall survival, and late-emergent safety results.<h4>Methods</h4>This multicentre, double-blind, ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2020, 21(11):1465-1477]

Cited: 22 times

View full text PDF listing >>



Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.

Sebastian Hultin, Kazi Nahar, Alexander M Menzies, Georgina V Long, Suran L Fernando, Victoria Atkinson, Jonathan Cebon, Muh Geot Wong,

<h4>Background</h4>Immune checkpoint inhibitors (ICI) have become the standard of care in many oncological conditions but are associated with a spectrum of renal immune-related adverse events (IrAEs). We aimed to describe the spectrum, histology, management and outcomes of renal IrAE in patients with metastatic melanoma undergoing ICI therapy.<h4>Methods</h4>We conducted a retrospective ... Read more >>

BMC Nephrol (BMC nephrology)
[2020, 21(1):391]

Cited: 0 times

View full text PDF listing >>



Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.

Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, John M Kirkwood, Vanna Chiarion Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Thierry Lesimple, Ruth Plummer, Kohinoor Dasgupta, Eduard Gasal, Monique Tan, Georgina V Long, Dirk Schadendorf,

<h4>Background</h4>In the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with <i>BRAF</i> V600E or V600K mutations. To confirm the stability of the relapse-free survival benefit, longer-term data ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 383(12):1139-1148]

Cited: 15 times

View full text PDF listing >>



The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.

Christoffer Gebhardt, Paolo Ascierto, Victoria Atkinson, Pippa Corrie, Reinhard Dummer, Dirk Schadendorf,

Patients with BRAF-mutant melanoma commonly develop resistance to BRAF inhibitor and MEK inhibitor (BRAF/MEKi) treatment, resulting in disease recurrence or progression. Repeated treatment after a break or an intervening therapy may provide clinical benefit. To ensure a common understanding when discussing the treatment of BRAF-mutant melanoma, we propose consensus definitions ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2020, 138:68-76]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.5471 s